This study is testing new drugs, pozelimab and cemdisiran, for adults with geographic atrophy (GA). GA is a condition caused by age-related macular degeneration (AMD), which affects the central part of the vision. The goal is to see if these drugs, alone or together, can slow down GA compared to a placebo (a treatment with no active drug). Researchers also want to know about possible side effects, how much drug enters the blood, and if the body creates antibodies against the drugs.

• The study involves injections and regular clinic visits.
• Participants must be willing to get specific vaccinations.
• There are specific criteria for who can join, like not having other eye diseases.

To join, participants need to have GA due to AMD, meet vision requirements, and agree to follow all study procedures, including vaccinations. They cannot join if they have other eye conditions or have had certain treatments recently. The study aims to find safe and effective treatments for this eye condition.